The «in vivo» study of blood 5-fluorouracil content by quenching of intrinsic protein fluorescence

Kayumova, R. R.; Султанбаев, А. В.; Ostakhov, S. S.; Хурсан, С. Л.; Абдуллин, М. И.; Gantsev, Shamil; Сакаева, Д. Д.

doi:10.1016/j.jlumin.2017.07.023

Cited by 3 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in the case of certain pharmaceuticals, the enteric administration (via the gastrointestinal tract) poses serious difficulties. Drug decomposition by acids and enzymes in the gastrointestinal tract (GI), lack of specificity, and localized therapeutic action are only a few of the setbacks encountered using this delivery method. , To tackle these challenges, the adsorption of the drug on a carrier, followed by its slow release in the targeted region, seems to be the most viable alternative. − Research efforts are being focused on the development of new, cheap, and accessible materials capable of adsorbing and releasing sizeable amounts of material. − Enteric administration of pharmaceuticals can produce both systemic and local effects in the GI. The lower GI tract poses a series of challenges for developing efficient drug delivery systems, particularly in anticancer research. , Targeted colon drug delivery is highly desirable because of the benefits of a sufficient amount of treatment at the organ site .…”

Section: Introductionmentioning

confidence: 99%

Novel Drug Carrier: 5-Fluorouracil Formulation in Nanoporous Biogenic Mg-calcite from Blue Crab Shells—Proof of Concept

et al. 2021

View full text Add to dashboard Cite

The ever-growing demand for novel, cheaper, and more effective drugs has put nanomedicine and targeted drug delivery to the forefront of scientific innovation. Owing to its porous three-dimensional (3D)-nanostructure and properties, the biogenic calcite from wasted blue crab shells is employed in the present work as a new drug carrier for 5-fluorouracil (5-FU), a drug widely used in cancer therapy. The drug solution has been loaded in the porous nanoarchitecture of the powdered biogenic material and further pelleted in tablets with a 5-FU concentration of 1.748 mg/g. Their structural and morphological properties were characterized using Raman, X-ray diffraction, and scanning electron microscopy. Confocal micro-Raman spectra of tablet surface showed a typical signal of biogenic carbonate with preserved carotenoids and carotenoproteins found in the native waste shell, while the drug Raman signal was absent, indicating its adsorption in the intricate nanoporous biogenic carrier. The slow release of the drug from the newly formulated tablet was investigated by tracking the surface-enhanced Raman scattering (SERS) signal of the tablet solution in a series of time-dependent experiments. The SERS signal quantification is achieved using the well-known SERS spectral fingerprint of 5-fluorouracil aqueous solution adsorbed on Ag nanoparticles. The proof of concept is demonstrated by quantifying the slow release of the drug through the characteristic SERS band intensity of 5-FU in a time course of 26 h. This proof of concept boosted further investigations concerning the released drug identity in simulated solutions that mimic the pH of the upper-and lower gastrointestinal tract, as well as the multiple possibilities to control porosity and composition during powdering and treatment of biogenic material, to achieve the most convenient formulation for relevant biomedical drug delivery. Nonetheless, the present results showed great promise for innovative reusing waste biogenic 3D-nanomaterials of aquatic origin as advantageous drug carriers for slow release purposes, in line with the concept of blue bioeconomy.

show abstract